| id | Study | Lib. in paper | Exposition period | Study type  | 
                Control type  | 
                Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S9751 R34819  | 
                Borthen (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2010 | Haemorrhage ≥ 500 ml | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No | 
                    0.79 [0.52;1.19] C  excluded (control group)  | 
                
                66/388 48/233 | 114 | 388 | 
                    
                    
                         | 
                ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9753 R34827  | 
                Borthen (Carbamazepine) (Controls unexposed, disease free), 2010 | Haemorrhage ≥ 500 ml | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, disease free excluded | Adjustment: Yes | 
                    1.30 [1.00;1.70]  excluded (control group)  | 
                
                66/388 49,252/362,302 | 49,318 | 388 | 
                    
                    
                         | 
                ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9755 R34835  | 
                Borthen (Carbamazepine) (Controls unexposed, sick), 2010 | Haemorrhage ≥ 500 ml | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: No | 1.18 [0.88;1.58] C | 66/388 276/1,863 | 342 | 388 | 
                    
                    
                         | 
                ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 1 studies | 1.18 [0.88;1.58] | 342 | 388 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Carbamazepine) (Controls unexposed, sick;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 9751, 9753